Fundz

Abcuro, Inc. reported raising $2.25 Million in an initial SEC Form D filing, from an offering of $2.25 Million

PRIVATEDec 13, 2016

Amount Raised

$2.25 Million

$2.25 Million sold, per SEC Form D (first sale Dec 13, 2016)

Round Type

Seed

NewtonvilleBiotechnologyHealth CareTherapeutics

Quick answer

Abcuro raised $2.25 Million in a Seed round, dated December 13, 2016. Abcuro is based in Newtonville, Massachusetts, United States.

How much did Abcuro raise?
Abcuro raised $2.25 Million in a Seed round on December 13, 2016.
What does Abcuro do?
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer..
Where is Abcuro based and how big is it?
Abcuro is based in Newtonville, Massachusetts, United States.
Who are the decision-makers at Abcuro?
Fundz holds 2 contacts at Abcuro, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Abcuro that raised within 45 days of this round, from Fundz verified event records.

  • Ovid Therapeutics raised $26M on January 20, 2017.
  • Rhythm Pharmaceuticals raised $20M on January 20, 2017.
  • BIOVIE INC. raised $200K (Pre-Seed) on January 19, 2017.
  • Galectin raised $3M (Seed) on January 6, 2017.
  • Rein Therapeutics, Inc. raised $30M on January 6, 2017.
  • Cue Biopharma raised $20M on December 22, 2016.

Who to call at Abcuro, and when

A new round usually means Abcuro is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Abcuro raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Abcuro, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Abcuro. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Abcuro

Location

55 Chapel Street Suite 200

Newtonville, Massachusetts, United States

About

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Abcuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsBrett C., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Abcuro's next move

See what Strategic adds

Abcuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.